Atrial fibrillation: hypertension as a causative agent, risk factor for complications, and potential therapeutic

Jeff S Healey1, Stuart J Connolly

  • 1McMaster University, Hamilton, Ontario, Canada.

Insights

Aggressively treating hypertension may prevent atrial fibrillation (AF) and reduce stroke risk. Managing high blood pressure can reverse cardiac changes that promote AF and its complications.

Area of Science:

  • Cardiology
  • Internal Medicine

Background:

  • Atrial fibrillation (AF) and hypertension are common, coexisting conditions increasing with age.
  • Hypertension contributes to cardiac structural changes favoring AF development and thromboembolic risk.
  • Current AF management prioritizes rate/rhythm control and anticoagulation, not hypertension treatment.

Purpose of the Study:

  • To explore the role of hypertension treatment in managing atrial fibrillation.
  • To investigate if aggressive hypertension management can prevent AF and its complications.

Main Methods:

  • Review of existing literature on the relationship between hypertension and atrial fibrillation.
  • Analysis of the impact of hypertension on cardiac structure and physiology.
  • Evaluation of potential benefits of pharmacotherapy for AF prevention.

Main Results:

  • Hypertension is linked to left ventricular hypertrophy, atrial enlargement, and slowed atrial conduction.
  • These cardiac changes increase AF incidence and thromboembolic risk.
  • Aggressive hypertension treatment may reverse structural changes and reduce AF occurrence.

Conclusions:

  • Hypertension management is crucial for preventing atrial fibrillation and its complications.
  • Pharmacotherapy targeting hypertension could be key in primary and secondary AF prevention.
  • Integrating aggressive blood pressure control into AF management strategies is warranted.

Related Concept Videos

Heart Failure Drugs: Inhibitors of Renin-Angiotensin System01:26

Heart Failure Drugs: Inhibitors of Renin-Angiotensin System

The activation of the sympathetic nervous system and the renin-angiotensin-aldosterone system (RAAS) contributes to cardiac remodeling, and inhibiting the RAAS is a pharmacological target in heart failure management. As a result, neurohumoral modulation is a crucial treatment principle for managing heart failure. This approach involves using medications like ACE inhibitors (ACEIs), angiotensin receptor blockers (ARBs), β-blockers, mineralocorticoid receptor antagonists (MRAs), and neutral...
Treatment for Pulmonary Arterial Hypertension: Receptor Tyrosine Kinase Inhibitors and Calcium Channel Blockers01:26

Treatment for Pulmonary Arterial Hypertension: Receptor Tyrosine Kinase Inhibitors and Calcium Channel Blockers

Receptor tyrosine kinase inhibitors (TKIs) and calcium channel blockers (CCBs) are two critical categories of drugs employed in the treatment of pulmonary artery hypertension (PAH). PAH is a disease that causes high blood pressure in the pulmonary arteries, resulting in chest pain, fatigue, and shortness of breath.
TKIs, such as imatinib (Gleevec), are particularly effective in tackling the growth and mitogenic factors that become upregulated in PAH patients. These factors contribute to the...
Heart Failure II: Pathophysiology01:29

Heart Failure II: Pathophysiology

Systolic Heart Failure and Compensatory MechanismsSystolic heart failure (also termed HFrEF, Heart Failure with Reduced Ejection Fraction) is the most prevalent type of heart filure. It results in a decreased volume of blood being pumped from the ventricle. The aortic arch and carotid sinuses have baroreceptors that detect reduced blood pressure, triggering the sympathetic nervous system (SNS) to release epinephrine and norepinephrine. Initially, this response aims to boost heart rate and...
Hypertension II: Pathophysiology01:29

Hypertension II: Pathophysiology

Hypertension is a chronic condition in which the blood's force against artery walls is excessively high, posing risks such as heart disease. The condition's underlying mechanisms involve complex interactions among the cardiovascular, kidney, and autonomic nervous systems.Renin-Angiotensin-Aldosterone System (RAAS): This system significantly influences blood pressure regulation. When blood pressure decreases, the kidneys secrete renin. This enzyme transforms angiotensinogen, a plasma protein,...
Hypertension III: Clinical Manifestations and Diagnostic Studies01:30

Hypertension III: Clinical Manifestations and Diagnostic Studies

Hypertension is asymptomatic and also referred to as the "silent killer" until it progresses to a severe stage or causes target organ disease. Patients may experience symptoms stemming from the strain on blood vessels and tissues in various organs or the heart's increased workload.Physical exams might show no abnormalities other than high blood pressure. Signs of vascular damage, when present, correspond to the organs supplied by the affected vessels, leading to target organ damage. For...
ECG Interpretation of Arrhythmias II: Atrial, Junctional and Ventricular Arrhythmias01:25

ECG Interpretation of Arrhythmias II: Atrial, Junctional and Ventricular Arrhythmias

Arrhythmia is a condition characterized by an irregular heart rhythm, with ECG changes that differ based on its origin and nature. The types of arrhythmias discussed below include atrial, junctional, and ventricular arrhythmias.Atrial ArrhythmiasPremature Atrial Complexes (PACs): PACs are early atrial beats caused by stress, caffeine, alcohol, electrolyte imbalances, hypoxia, hyperthyroidism, or certain medications (e.g., bronchodilators and decongestants). The ECG shows early P waves with an...